Nurix Therapeutics (NRIX) Competitors

$16.12 -0.06 (-0.34%)

As of 10:29 AM Eastern

NRIX vs. ACLX, KYMR, PTGX, COGT, and BLTE

Should you buy Nurix Therapeutics stock or one of its competitors? MarketBeat compares Nurix Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nurix Therapeutics include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Nurix Therapeutics compare to Arcellx?

Arcellx (NASDAQ:ACLX) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcellx has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market.

Arcellx presently has a consensus target price of $111.87, indicating a potential downside of 2.78%. Nurix Therapeutics has a consensus target price of $30.46, indicating a potential upside of 88.70%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Nurix Therapeutics had 5 more articles in the media than Arcellx. MarketBeat recorded 5 mentions for Nurix Therapeutics and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Nurix Therapeutics' score of 0.73 indicating that Arcellx is being referred to more favorably in the media.

Company	Overall Sentiment
Arcellx	Positive
Nurix Therapeutics	Positive

Arcellx has higher earnings, but lower revenue than Nurix Therapeutics. Arcellx is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Nurix Therapeutics	$83.98M	19.88	-$264.46M	-$3.16	N/A

Nurix Therapeutics has a net margin of -411.37% compared to Arcellx's net margin of -1,027.26%. Arcellx's return on equity of -55.42% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Summary

Nurix Therapeutics beats Arcellx on 9 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Nurix Therapeutics has a net margin of -411.37% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Nurix Therapeutics currently has a consensus price target of $30.46, suggesting a potential upside of 88.70%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 38.39%. Given Nurix Therapeutics' higher possible upside, equities analysts clearly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Nurix Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market.

Nurix Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.88	-$264.46M	-$3.16	N/A
Kymera Therapeutics	$39.21M	179.03	-$311.35M	-$3.57	N/A

In the previous week, Kymera Therapeutics had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 11 mentions for Kymera Therapeutics and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.73 beat Kymera Therapeutics' score of 0.32 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nurix Therapeutics and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Protagonist Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	90.44	-$130.15M	-$1.81	N/A
Nurix Therapeutics	$83.98M	19.88	-$264.46M	-$3.16	N/A

Protagonist Therapeutics has a net margin of -154.88% compared to Nurix Therapeutics' net margin of -411.37%. Protagonist Therapeutics' return on equity of -17.76% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Protagonist Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Nurix Therapeutics. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.73 beat Protagonist Therapeutics' score of 0.10 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics presently has a consensus price target of $113.69, indicating a potential upside of 9.16%. Nurix Therapeutics has a consensus price target of $30.46, indicating a potential upside of 88.70%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Cogent Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Cogent Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market.

In the previous week, Cogent Biosciences had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Cogent Biosciences and 5 mentions for Nurix Therapeutics. Cogent Biosciences' average media sentiment score of 0.98 beat Nurix Therapeutics' score of 0.73 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Nurix Therapeutics	$83.98M	19.88	-$264.46M	-$3.16	N/A

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 25.24%. Nurix Therapeutics has a consensus price target of $30.46, indicating a potential upside of 88.70%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Nurix Therapeutics beats Cogent Biosciences on 9 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Belite Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Belite Bio's return on equity of -19.49% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Belite Bio has higher earnings, but lower revenue than Nurix Therapeutics. Belite Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Nurix Therapeutics	$83.98M	19.88	-$264.46M	-$3.16	N/A

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Belite Bio currently has a consensus target price of $202.33, indicating a potential upside of 34.53%. Nurix Therapeutics has a consensus target price of $30.46, indicating a potential upside of 88.70%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Belite Bio had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Belite Bio and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.73 beat Belite Bio's score of 0.72 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market.

Summary

Belite Bio and Nurix Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$3.41B	$6.30B	$12.38B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-5.11	18.62	20.95	25.53
Price / Sales	19.88	288.83	549.40	73.70
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.05	6.68	9.81	6.62
Net Income	-$264.46M	$24.11M	$3.55B	$333.63M
7 Day Performance	-0.84%	-1.64%	-1.04%	-0.33%
1 Month Performance	-0.96%	-0.72%	0.67%	3.48%
1 Year Performance	68.51%	75.86%	40.04%	35.08%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	2.7188 of 5 stars	$16.14 -0.2%	$30.46 +88.7%	+66.3%	$1.67B	$83.98M	N/A	300
ACLX Arcellx	2.5141 of 5 stars	$115.07 flat	$111.87 -2.8%	+97.5%	$6.73B	$22.29M	N/A	80	High Trading Volume
KYMR Kymera Therapeutics	2.3747 of 5 stars	$83.59 +3.6%	$118.70 +42.0%	+174.9%	$6.64B	$39.21M	N/A	170	Insider Trade
PTGX Protagonist Therapeutics	1.817 of 5 stars	$99.52 +1.2%	$108.15 +8.7%	+134.7%	$6.33B	$46.02M	N/A	120	Insider Trade
COGT Cogent Biosciences	3.3111 of 5 stars	$36.73 +0.3%	$43.45 +18.3%	+587.2%	$6.26B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. ACLX, KYMR, PTGX, COGT, and BLTE

How does Nurix Therapeutics compare to Arcellx?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Summary

How does Nurix Therapeutics compare to Cogent Biosciences?

Summary

How does Nurix Therapeutics compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. ACLX, KYMR, PTGX, COGT, and BLTE

How does Nurix Therapeutics compare to Arcellx?

Do insiders & institutionals have more ownership in ACLX or NRIX?

Which has more risk & volatility, ACLX or NRIX?

Do analysts rate ACLX or NRIX?

Does the media favor ACLX or NRIX?

Which has higher valuation and earnings, ACLX or NRIX?

Is ACLX or NRIX more profitable?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Is NRIX or KYMR more profitable?

Do analysts rate NRIX or KYMR?

Which has more volatility & risk, NRIX or KYMR?

Which has higher valuation & earnings, NRIX or KYMR?

Does the media favor NRIX or KYMR?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Which has higher earnings and valuation, PTGX or NRIX?

Is PTGX or NRIX more profitable?

Which has more volatility & risk, PTGX or NRIX?

Does the media prefer PTGX or NRIX?

Do analysts rate PTGX or NRIX?

Do insiders and institutionals have more ownership in PTGX or NRIX?

Summary

How does Nurix Therapeutics compare to Cogent Biosciences?

Is COGT or NRIX more profitable?

Which has more volatility & risk, COGT or NRIX?

Does the media prefer COGT or NRIX?

Which has higher earnings and valuation, COGT or NRIX?

Do analysts prefer COGT or NRIX?

Summary

How does Nurix Therapeutics compare to Belite Bio?

Is BLTE or NRIX more profitable?

Which has stronger valuation & earnings, BLTE or NRIX?

Do institutionals & insiders believe in BLTE or NRIX?

Do analysts recommend BLTE or NRIX?

Does the media favor BLTE or NRIX?

Which has more volatility and risk, BLTE or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools